DGX Quest Diagnostics
- 143.870
- +2.910+2.06%
Quest Diagnostics News
Quest Diagnostics Analyst Ratings
Baird Adjusts Price Target on Quest Diagnostics to $154 From $153
BofA Securities Maintains Quest Diagnostics(DGX.US) With Buy Rating, Maintains Target Price $150
Truist Financial Maintains Quest Diagnostics(DGX.US) With Hold Rating
A Quick Look at Today's Ratings for Quest Diagnostics(DGX.US), With a Forecast Between $144 to $154
Quest Diagnostics: A Balanced Hold Rating Amidst Modest Growth and Market Volatility
Leerink Partners Adjusts Quest Diagnostics Price Target to $154 From $151, Maintains Market Perform Rating
Buy Rating Affirmed for Quest Diagnostics Amid Strong Q2 Financials and Upbeat 2024 Guidance
Quest Diagnostics Analyst Ratings
Truist Securities Adjusts Price Target on Quest Diagnostics to $158 From $150, Maintains Hold Rating
Citi Upgrades Illumina, Quest, Agilent to Buy, Downgrades Avantor
Quest Diagnostics Analyst Ratings
Citigroup Upgrades Quest Diagnostics to Buy From Neutral, Adjusts Price Target to $165 From $145
Analysts' Opinions Are Mixed on These Healthcare Stocks: CureVac (CVAC), Insmed (INSM) and Quest Diagnostics (DGX)
Quest Diagnostics Analyst Ratings
Baird Adjusts Price Target on Quest Diagnostics to $153 From $145, Maintains Neutral Rating
Barclays Sticks to Their Hold Rating for Quest Diagnostics (DGX)
Buy Rating Affirmed: Quest Diagnostics' Strategic Acquisition of LifeLabs Poised to Boost Growth and Profitability
Nephron Adjusts Price Target on Quest Diagnostics to $155 From $152
Quest Diagnostics Analyst Ratings
Analysis
Price Target
No Data
